Previous 10 | Next 10 |
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3 m...
ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years PARSIPPANY, NJ, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its agreement with LabCorp ® (NYSE: LH) has been extended for an additional two years, throug...
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics’ ThyraMIR ® miRNA classifier for evaluating indete...
Ron Rocca, CEO of Exagen, appointed to Board James Early, CFO announces retirement; Fred Knechtel, formerly CFO of GENEWIZ, appointed as CFO Jeff Salzman, formerly of CareDX, appointed VP of Managed Care & Payer Relations PARSIPPANY, NJ, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Int...
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and phar...
The opportunity in Interpace ( IDXG ) represents highly compelling upside at a very favorable entry. At about $70 million market cap (fully diluted pro forma for the recent financing), just a move to lower end peer multiples can almost triple the value of the company to be conservative even ...
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) (...
Interpace Biosciences (NASDAQ: IDXG ) is up 15% premarket on entering into a collaborative study with University of North Carolina to explore the potential use of BarreGEN in patients undergoing radiofrequency ablation (RFA). More news on: Interpace Biosciences, Inc., He...
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary, Interpace Diagnostics has entered into a collaborative study aimed at exploring t...
Interpace Biosciences' (NASDAQ: IDXG ) Medicare Administrative Contractor (MAC) announces a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT test, representing an increase of ~$2,400 per assay over previous reimbursement coverage. More news on: Interpa...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...